[
  {
    "ts": null,
    "headline": "Biogen proposes to buy remaining stake in Sage in $442 million deal",
    "summary": "Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade. ...",
    "url": "https://finnhub.io/api/news?id=e33fe47c161bd55fbdbe04aec4e8af66447ff06b3e7f4c4bc8adefdba4b0edb1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736534372,
      "headline": "Biogen proposes to buy remaining stake in Sage in $442 million deal",
      "id": 132374607,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade. ...",
      "url": "https://finnhub.io/api/news?id=e33fe47c161bd55fbdbe04aec4e8af66447ff06b3e7f4c4bc8adefdba4b0edb1"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains",
    "summary": "(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Companies including Biogen I",
    "url": "https://finnhub.io/api/news?id=ea5f36bfd3b0ac504e35d4fa86745f94ba1329858e30a5dc962073caa485c682",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736485200,
      "headline": "Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains",
      "id": 132357051,
      "image": "https://media.zenfs.com/en/bloomberg_markets_842/29e857c7f809eb552ddff0361e37d60e",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeAmbitious High-Speed Rail Plans Advance in the Baltic RegionDutch Central Bank Restores Amsterdam’s ‘Ugliest Building’Companies including Biogen I",
      "url": "https://finnhub.io/api/news?id=ea5f36bfd3b0ac504e35d4fa86745f94ba1329858e30a5dc962073caa485c682"
    }
  },
  {
    "ts": null,
    "headline": "NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration",
    "summary": "NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.",
    "url": "https://finnhub.io/api/news?id=a9f3641c501e6bded39b760bceadb26505bf805937725f8186845afbf298946d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736483843,
      "headline": "NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration",
      "id": 132359861,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91156685/image_91156685.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's potential impact on NGENF's stock value.",
      "url": "https://finnhub.io/api/news?id=a9f3641c501e6bded39b760bceadb26505bf805937725f8186845afbf298946d"
    }
  }
]